Group 1 - The core stock price of Beilu Pharmaceutical (300016) closed at 9.44 yuan on January 12, 2026, with an increase of 2.39% and a turnover rate of 8.34%, resulting in a trading volume of 469,100 shares and a transaction amount of 439 million yuan [1] - The company reported significant revenue growth from its export products, primarily contrast agents and raw materials, covering markets in South America, Africa, and Asia [2] - The overall gross margin for the company's overseas business in 2024 was only 17.57%, significantly lower than the disclosed gross margin of 49.2% for contrast agents, attributed to a higher proportion of raw materials in the export revenue structure [2] Group 2 - On January 12, the net inflow of main funds into Beilu Pharmaceutical was 7.25 million yuan, indicating positive engagement from major investors [3] - The net inflow of speculative funds was 4.87 million yuan, while retail investors experienced a net outflow of 12.12 million yuan [4]

Group 1 - The core viewpoint of the article is that Beilu Pharmaceutical holds a significant stake in Yiwei Medical, which is a leading AI company in China focused on brain diseases, covering the entire process from screening to diagnosis and rehabilitation [1] - Beilu Pharmaceutical currently owns 14.9881% of Yiwei Medical, making it the second-largest shareholder [1] - Yiwei Medical specializes in non-invasive brain-machine interfaces, neuroregulation, and medical AI, targeting essential scenarios such as stroke, Alzheimer's disease, and cognitive disorders [1]